B P Roques

4.4k total citations · 3 hit papers
64 papers, 3.8k citations indexed

About

B P Roques is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Oncology. According to data from OpenAlex, B P Roques has authored 64 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Cellular and Molecular Neuroscience, 35 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in B P Roques's work include Neuropeptides and Animal Physiology (37 papers), Peptidase Inhibition and Analysis (19 papers) and Receptor Mechanisms and Signaling (13 papers). B P Roques is often cited by papers focused on Neuropeptides and Animal Physiology (37 papers), Peptidase Inhibition and Analysis (19 papers) and Receptor Mechanisms and Signaling (13 papers). B P Roques collaborates with scholars based in France, Belgium and United Kingdom. B P Roques's co-authors include M C Fournié-Zaluski, Bernard Malfroy, J.C. Schwartz, Florence Noble, Ann Beaumont, V. Daugé, Jean-Paul Swerts, Catherine Llorens‐Cortés, Jeanne‐Marie Lecomte and Gilles Waksman and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

B P Roques

64 papers receiving 3.6k citations

Hit Papers

Neutral endopeptidase 24.11: structure, inhibition, and e... 1978 2026 1994 2010 1993 1980 1978 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
    1993 647 citations B P Roques, Florence Noble et al. profile →
  2. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice
    1980 614 citations B P Roques, M C Fournié-Zaluski et al. profile →
  3. High-affinity enkephalin-degrading peptidase in brain is increased after morphine
    1978 554 citations B P Roques et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B P Roques France 30 2.4k 2.0k 1.1k 1.0k 341 64 3.8k
M C Fournié-Zaluski France 29 1.9k 0.8× 1.7k 0.9× 974 0.9× 855 0.8× 434 1.3× 68 3.5k
Marie‐Claude Fournié‐Zaluski France 41 2.0k 0.9× 2.1k 1.1× 882 0.8× 966 1.0× 486 1.4× 102 3.8k
Sherwin Wilk United States 42 2.1k 0.9× 3.1k 1.5× 1.9k 1.7× 514 0.5× 303 0.9× 124 5.6k
Emanuela Bonfoco United States 17 1.5k 0.6× 3.2k 1.6× 488 0.4× 783 0.8× 94 0.3× 19 5.3k
Javier Navarro United States 32 1.3k 0.5× 2.6k 1.3× 576 0.5× 393 0.4× 125 0.4× 80 3.9k
Lester R. Drewes United States 37 978 0.4× 2.2k 1.1× 764 0.7× 1.3k 1.3× 63 0.2× 103 5.3k
Scott M. DeWire United States 19 1.9k 0.8× 3.0k 1.5× 478 0.4× 420 0.4× 359 1.1× 21 3.8k
Ichiro Aramori Japan 29 1.1k 0.5× 2.5k 1.2× 300 0.3× 2.2k 2.2× 1.1k 3.2× 54 5.0k
Raymond B. Penn United States 44 2.1k 0.9× 4.6k 2.3× 472 0.4× 2.2k 2.2× 254 0.7× 117 7.0k
Anthony J. Turner United Kingdom 33 694 0.3× 1.6k 0.8× 600 0.5× 1.3k 1.2× 283 0.8× 90 3.3k

Countries citing papers authored by B P Roques

Since Specialization
Citations

This map shows the geographic impact of B P Roques's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B P Roques with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B P Roques more than expected).

Fields of papers citing papers by B P Roques

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B P Roques. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B P Roques. The network helps show where B P Roques may publish in the future.

Co-authorship network of co-authors of B P Roques

This figure shows the co-authorship network connecting the top 25 collaborators of B P Roques. A scholar is included among the top collaborators of B P Roques based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B P Roques. B P Roques is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hurtrel, Bruno, Emmanuel Moreau, Bernard A. P. Lafont, et al.. (2004). Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine. 23(11). 1399–1407. 9 indexed citations
2.
Wecker, Karine, Nelly Morellet, Serge Bouaziz, & B P Roques. (2002). NMR structure of the HIV‐1 regulatory protein Vpr in H2O/trifluoroethanol. European Journal of Biochemistry. 269(15). 3779–3788. 50 indexed citations
3.
Noble, Florence, Mária Szűcs, Brigitte L. Kieffer, & B P Roques. (2000). Overexpression of Dynamin Is Induced by Chronic Stimulation of μ- but Not δ-Opioid Receptors: Relationships with μ-Related Morphine Dependence. Molecular Pharmacology. 58(1). 159–166. 32 indexed citations
4.
Hutcheson, Daniel M., Fazal Subhan, David Pache, et al.. (2000). Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties. European Journal of Pharmacology. 401(2). 197–204. 9 indexed citations
5.
Gonzalez, Walter G., Jean-Marc Soleilhac, M C Fournié-Zaluski, B P Roques, & Jean‐Baptiste Michel. (1998). Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. European Journal of Pharmacology. 345(3). 323–331. 45 indexed citations
6.
Hernando, Fernando, JoséA. Fuentes, Marie‐Claude Fournié‐Zaluski, B P Roques, & Mariano Ruiz‐Gayo. (1996). Antidepressant-like effects of CCKB receptor antagonists: involvement of the opioid system. European Journal of Pharmacology. 318(2-3). 221–229. 18 indexed citations
7.
Valverde, Olga, et al.. (1995). Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. European Journal of Pharmacology. 286(1). 79–93. 15 indexed citations
8.
Valverde, Olga, Rafaël Maldonado, M C Fournié-Zaluski, & B P Roques. (1994). Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.. Journal of Pharmacology and Experimental Therapeutics. 270(1). 77–88. 73 indexed citations
9.
Perrot, Serge, Valérie Kayser, Marie‐Claude Fournié‐Zaluski, B P Roques, & G. Guilbaud. (1993). Antinociceptive effect of systemic PC 12, a prodrug mixed inhibitor of enkephalin-degrading enzymes, in normal and arthritic rats. European Journal of Pharmacology. 241(1). 129–133. 13 indexed citations
10.
Pham, I., Abdelaziz Amrani, M C Fournié-Zaluski, et al.. (1993). Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.. Journal of Pharmacology and Experimental Therapeutics. 265(3). 1339–1347. 76 indexed citations
11.
Gómez‐Monterrey, Isabel, et al.. (1993). Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors. Journal of Medicinal Chemistry. 36(1). 87–94. 22 indexed citations
12.
Boucheix, Claude, et al.. (1992). Effects of monoclonal antibodies raised against the common acute lymphoblastic leukemia antigen on endopeptidase-24.11 activity. Biochemical Pharmacology. 43(4). 809–814. 4 indexed citations
13.
14.
Giocondi, Marie‐Cécile, et al.. (1992). Detection of neutral endopeptidase-24.11/CD10 by flow cytometry and photomicroscopy using a new fluorescent inhibitor. Analytical Biochemistry. 205(1). 57–64. 3 indexed citations
15.
Noble, Florence, Serge Turcaud, Marie‐Claude Fournié‐Zaluski, & B P Roques. (1992). Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. European Journal of Pharmacology. 223(1). 83–89. 46 indexed citations
16.
Laufer, Ralph, et al.. (1991). Pseudopeptide analogs of substance P and leucine enkephalinamide containing the .psi.(methyleneoxy) modification: synthesis and biological activity. Journal of Medicinal Chemistry. 34(8). 2430–2438. 23 indexed citations
17.
Delay‐Goyet, Philippe, Mariano Ruiz‐Gayo, Ana Baamonde, et al.. (1991). Brain passage of BUBU, a highly selective and potent agonist for δ opioid receptors: In vivo binding and μ versus δ receptors occupancy. Pharmacology Biochemistry and Behavior. 38(1). 155–162. 18 indexed citations
18.
Laugâa, Philippe, et al.. (1988). NMR Studies of Tris-Intercalation: Solution Structure and Interaction of d(CTTCGCGCGAAG) with an Acridine Trimer. Journal of Biomolecular Structure and Dynamics. 6(3). 421–441. 3 indexed citations
19.
Witte, Ph. De, Christian Heidbreder, B P Roques, & J.J. Vanderhaeghen. (1987). Opposite effects of cholecystokinin octapeptide (CCK-8) and tetrapeptide (CCK-4) after injection into the caudal part of the nucleus accumbens or into its rostral part and the cerebral ventricles. Neurochemistry International. 10(4). 473–479. 43 indexed citations
20.
Bourgoin, S., Daniel Le Bars, F. Artaud, et al.. (1986). Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of methionine-enkephalin-like material from the rat spinal cord.. Journal of Pharmacology and Experimental Therapeutics. 238(1). 360–366. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M C Fournié-Zaluski Breakdown of academic impact, for papers by Marie‐Claude Fournié‐Zaluski Breakdown of academic impact, for papers by Sherwin Wilk Breakdown of academic impact, for papers by Emanuela Bonfoco Breakdown of academic impact, for papers by Javier Navarro Breakdown of academic impact, for papers by Lester R. Drewes Breakdown of academic impact, for papers by Scott M. DeWire Breakdown of academic impact, for papers by Ichiro Aramori Breakdown of academic impact, for papers by Raymond B. Penn Breakdown of academic impact, for papers by Anthony J. Turner
Rankless by CCL
2026